Product Images Gemcitabine
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Gemcitabine NDC 72485-223 by Armas Pharmaceuticals Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
structural formula - Image01
Figure 1 - Image02
This is a description of the median progression-free survivals for two different treatments: Gemcitabine/Carboplatin at 8.6 months versus Carboplatin alone at 5.8 months. The log rank p-value for the difference between these treatments is reported as 0.0038. The corresponding probability of progression-free survival curves for each treatment is shown graphically.*
Figure 2 - Image03
This text provides information on Median Time to Documented Disease Progression for two different treatments, Gemcitabine/Paclitaxel and Paclitaxel. It shows that Gemcitabine/Paclitaxel had a statistically significant longer progression-free time compared to Paclitaxel, with a logrank p-value of <0.0001. The graph shows the probability of progression-free survival over time for each treatment group, with Gemcitabine/Paclitaxel having a higher probability of being progression-free over time.*
Figure 3 - Image04
This is a table displaying the median survival and 1-year survival rates for patients with two different treatments. The first treatment (Gemcitabine/Cisplatin) has a median survival of 9.0 months and a 1-year survival rate of 39%, while the second treatment (Cisplatin) has a median survival of 7.6 months and a 1-year survival rate of 28%. The table also includes a graph showing the survival probability over time for each treatment, as well as the test statistics and p-values for the Logrank and Wilcoxon tests comparing the two treatments. The data is based on a total of 522 patients (260 in the Gemcitabine/Cisplatin group and 262 in the Cisplatin group) and the survival time is measured in months.*
Figure 4 - Image05
This appears to be a graph or chart showing the "Fraction Surviving" over "Survival Time (months)" for a treatment called "Gemcitabine." Without additional context or data, it is difficult to provide further analysis.*
Vial - Image8
This is a description of a vial of Gemcitabine Injection, for intravenous infusion only. The vial contains 2g of gemcitabine (equivalent to 10 2.277g of gemcitabine hydrochloride) and water for injection, with hydrochloric acid and/or sodium hydroxide added to adjust pH. The label provides information regarding dosing and administration and storage instructions. The product is packaged in a 52.6 mL single-dose vial and is manufactured by Shilpa Medicare Limited in India and distributed by Armas Pharmaceuticals in the USA. The label also warns that it is a cytotoxic agent. The text seems to be complete and legible.*
Carton - Image9
This is the outer carton label for Gemcitabine, a cytotoxic agent produced by Ronly. Each vial of 52.6 mL contains 2g of gemcitabine hydrochloride and water for injection, USP. Before dosing and administration, the package insert and code TSDRUGS2013 should be consulted as well as the warning on the label. The drug should be prevented from inhalation to avoid exposure to potentially harmful particles, and it should only be used for intravenous infusion once diluted. Gemcitabine should be stored between 2 to 8 degrees Celsius and the unused portion discarded. The product is distributed by Amas Pharmaceuticals, Inc. The remaining text contains duplicate information.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
